查看文章

Venetoclax in combination with azacitidine or decitabine (HMA+ Ven) is the standard-of-care treatment for older adults (≥ 75 years) or those with comorbidities precluding intensive induction therapy in newly diagnosed acute myeloid leukemia (AML). Tumor lysis syndrome (TLS) and infectious complications are two of the most concerning adverse events with this regimen. Ven ramp up is recommended to prevent TLS. However, incidence of real world TLS and infectious complications with and without Ven ramp up are unknown. We retrospectively analyzed patients with newly diagnosed and relapsed/refractory AML who received HMA+ Ven from 02/17–05/21 at our cancer center. Demographics, AML characteristics, treatment details, TLS parameters, and infectious complications were collected. TLS was defined as per Cairo-Bishop definition. Two-sided Mann-Whitney U test and …